MaxCyte MXCT Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MaxCyte in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about MaxCyte's business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MaxCyte's business segments — net income loss?
- MaxCyte (MXCT) reported business segments — net income loss of -$4.75M in Q1 2026.
- How has MaxCyte's business segments — net income loss changed year-over-year?
- MaxCyte's business segments — net income loss increased by 53.7% year-over-year, from -$10.26M to -$4.75M.
- What is the long-term trend for MaxCyte's business segments — net income loss?
- Over 2 years (2023 to 2025), MaxCyte's business segments — net income loss has grown at a 8.5% compound annual growth rate (CAGR), from -$37.92M to -$44.63M.
- What does business segments — net income loss mean?
- This metric represents the final bottom-line financial result for the cell engineering technology segment after accounting for all revenues, operating expenses, and non-operating items. It serves as the primary indicator of the segment's overall financial performance and its ability to generate sustainable returns from its proprietary platform technologies. A positive value indicates profitability, while a negative value reflects a loss for the reporting period.